In vitro Gram-positive antimicrobial activity of evernimicin (SCH 27899), a novel oligosaccharide, compared with other antimicrobials: A multicentre international trial

Journal of Antimicrobial Chemotherapy

Volumn 47, Issue 1, 2001, Pages 15-25

  Jones, R N ^a,c   Hareb, R S ^b   Sabatelli, F J ^b   Aldridge, K ^c   Della Latta, P ^c   Ferraro, M J ^c   Goering, R ^c   Hindkler, J ^c   Bruckner, D ^c   Jacobs, M ^c   Low, D ^c   Medeiros, A ^c   Boyce, J ^c   Murray, B ^c   Baquero, F ^c   Costa, D ^c   Frimodt Moller N ^c   Goossens, H ^c   Graninger, D ^c   Gudmundsson, S ^c   Gur, D ^c   Huovinen, P ^c   Kettner, M ^c   Keuleyen, E ^c   Klugman, K ^c   Le Clercq, R ^c   Patzer, J ^c   Petrikkos, G ^c   Lingaas, E ^c   Nord, C ^c   Reshedko, G ^c   Stratchounski, L ^c   Schindler, J ^c   Schito, G C ^c   Jones, M E ^c   Wiedemann, B ^c   Wise, R ^c   more..

^a UNIVERSITY OF IOWA   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c 345 Beaver Kreek Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; CEFOTAXIME; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; DALFOPRISTIN; ERYTHROMYCIN; EVERNIMICIN; GENTAMICIN; METICILLIN; OLIGOSACCHARIDE; OXACILLIN; PENICILLIN G; QUINUPRISTIN; STREPTOMYCIN; VANCOMYCIN;

ANALYTIC METHOD; ANTIMICROBIAL ACTIVITY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; EASTERN EUROPE; ENTEROCOCCUS; GRAM POSITIVE BACTERIUM; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NORTH AMERICA; QUALITY CONTROL; RELIABILITY; REPRODUCIBILITY; SCANDINAVIA; SOUTH AFRICA; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; TURKEY (REPUBLIC); WESTERN EUROPE;

EID: 0035185995     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/47.1.15     Document Type: Article

References (32)

1. Gram-positive resistance: Challenge for the development of new antibiotics
2. Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci
3. Nosocomial enterococcal blood stream infections in the SCOPE Program: Antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE hospital study group
4. The role of fourth-generation cephalosporins in the treatment of infectious caused by penicillin-resistant streptococci
5. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997)
6. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study
7. Predominant pathogens in hospital infections
8. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
9. Emergence of vancomycin resistance in coagulase-negative staphylococci
10. Clinical implications of nosocomial gram-positive bacteremia and superimposed antimicrobial resistance
11. Pharmacological properties of everninomicin D
12. Chemical modification of everninomycins
13. Microbiological characterization of everninomicin B and D
14. The structure of new oligosaccharide antibiotics, 13-384 components 1 and 5
15. Determination of the absolute stereochemistry at the C16 orthoester of everninomycin antibiotics: A novel acid-catalyzed isomerization of orthoesters
16. Structure of Everninomicin D-1
17. Antimicrobial activity of SCH 27899, oligosaccharide member of the everninomicin class with a wide gram-positive spectrum
18. Antimicrobial activity and spectrum of SCH27899 (Ziracin®) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control
19. Antimicrobial activity of SCH27899 (Ziracin®), a novel everninomicin derivative, tested against Streptococcus spp.: Disk diffusion/Etest method evaluations and quality control guidelines
20. Everninomicin, a new oligosaccharide antibiotic: Its anti-microbial activity, post-antibiotic effect and synergistic bactericidal activity
21. Comparative in-vitro activity of SCH27899, a novel everninomicin, and vancomycin
22. The emergent needs for basic research, education, and surveillance of antimicrobial resistance: Problems facing the report from the American Society of Microbiology Task Force on Antibiotic Resistance
23. A novel technique for direct quantitation of antimicrobial susceptibility of microorganisms
24. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada
25. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis (NCTC12201 to Straphylococcus aureus
26. Influence of erythromycin resistance, inoculum growth phase and incubation time on assessment of the bactericidal activity of RP 59500 (quinupristin-dalfopristin) against vancomycin-resistant Enterococcus faecium
27. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia
28. The National Nosocomial Infection Surveillance System. Ciprofloxacin resistance among nosocomial Pseudomonas aeruginosa and Staphylococcus aureus in the United States
29. Prevalence of fluoroquinolone resistance in Europe. Study group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy e.v.
30. Association between decreased susceptibility to a new antibiotic for treatment of human diseases, everninomicin (SC27899), and resistance to an antibiotic used for growth promotion in animals, avilamycin